MX394249B - Sistema de suministro transdermico de donepezilo. - Google Patents

Sistema de suministro transdermico de donepezilo.

Info

Publication number
MX394249B
MX394249B MX2019001103A MX2019001103A MX394249B MX 394249 B MX394249 B MX 394249B MX 2019001103 A MX2019001103 A MX 2019001103A MX 2019001103 A MX2019001103 A MX 2019001103A MX 394249 B MX394249 B MX 394249B
Authority
MX
Mexico
Prior art keywords
transdermal delivery
donepezil
delivery system
therapeutic agent
donepezil transdermal
Prior art date
Application number
MX2019001103A
Other languages
English (en)
Spanish (es)
Other versions
MX2019001103A (es
Inventor
Amit K Jain
Eun Soo Lee
Parminder Singh
Original Assignee
Corium Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corium Int Inc filed Critical Corium Int Inc
Publication of MX2019001103A publication Critical patent/MX2019001103A/es
Publication of MX394249B publication Critical patent/MX394249B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0016—Plasticisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019001103A 2016-07-27 2017-07-26 Sistema de suministro transdermico de donepezilo. MX394249B (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662367502P 2016-07-27 2016-07-27
US201662367542P 2016-07-27 2016-07-27
US201662423133P 2016-11-16 2016-11-16
US201762444745P 2017-01-10 2017-01-10
US201762444763P 2017-01-10 2017-01-10
US201762457794P 2017-02-10 2017-02-10
US201762504391P 2017-05-10 2017-05-10
US201762504408P 2017-05-10 2017-05-10
PCT/US2017/044050 WO2018022817A1 (en) 2016-07-27 2017-07-26 Donepezil transdermal delivery system

Publications (2)

Publication Number Publication Date
MX2019001103A MX2019001103A (es) 2019-09-27
MX394249B true MX394249B (es) 2025-03-24

Family

ID=59523314

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001103A MX394249B (es) 2016-07-27 2017-07-26 Sistema de suministro transdermico de donepezilo.
MX2022006681A MX2022006681A (es) 2016-07-27 2019-01-25 Sistema de suministro transdermico de donepezilo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022006681A MX2022006681A (es) 2016-07-27 2019-01-25 Sistema de suministro transdermico de donepezilo.

Country Status (10)

Country Link
US (13) US20180028463A1 (enExample)
EP (3) EP3490541B1 (enExample)
JP (6) JP7071330B2 (enExample)
KR (9) KR102406482B1 (enExample)
CN (5) CN109789106B (enExample)
AU (7) AU2017302307A1 (enExample)
CA (2) CA3032044C (enExample)
MX (2) MX394249B (enExample)
SG (1) SG11201900692WA (enExample)
WO (3) WO2018022817A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015371308A1 (en) 2014-12-23 2017-08-03 Intellectual Property Associates, Llc Methods and formulations for transdermal administration
MX2018006192A (es) * 2015-11-18 2018-12-19 Commw Scient Ind Res Org Grano de arroz con aleurona engrosada.
RU2737464C2 (ru) 2015-12-30 2020-11-30 Кориум Интернэшнл, Инк. Системы и способы длительного трансдермального введения
WO2017223402A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
KR102508993B1 (ko) 2016-07-27 2023-03-10 코리움, 인크. 메만틴 경피 송달 시스템
US20180028463A1 (en) 2016-07-27 2018-02-01 Corium International Inc. Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug
WO2019023499A1 (en) * 2017-07-26 2019-01-31 Corium International, Inc. TRANSDERMAL DELIVERY SYSTEM WITH MICROPOROUS MEMBRANE HAVING SOLVENT FILLED PORES
JP2020534285A (ja) 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 投与および処置の方法
AU2018392686A1 (en) 2017-12-20 2020-07-09 Corium Pharma Solutions, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
KR102710072B1 (ko) * 2018-08-31 2024-09-24 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR102823139B1 (ko) * 2018-08-31 2025-06-19 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR102115102B1 (ko) 2018-12-21 2020-05-26 동아에스티 주식회사 안정화된 도네페질 함유 경피 흡수제제
US11101101B2 (en) * 2019-05-15 2021-08-24 Fei Company Laser-based phase plate image contrast manipulation
KR102372630B1 (ko) * 2019-05-15 2022-03-14 주식회사 대웅제약 고함량의 도네페질 또는 그의 염을 포함하는 경피흡수제제
CA3154505A1 (en) * 2019-10-24 2021-04-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of fingolimod
US20230015492A1 (en) * 2019-11-26 2023-01-19 Hisamitsu Pharmaceutical Co., Inc. Method for improving holding power of adhesive agent layer of ropinirole-containing patch, and ropinirole-containing patch with improved holding power
US20230357787A1 (en) * 2019-12-18 2023-11-09 Pioneer Hi-Bred International, Inc. Compositions and methods for improving grain yield in plants
MX2022012841A (es) * 2020-04-14 2022-12-02 Glanis Pharmaceuticals Inc Sistema de entrega transdérmica y/o tópica que comprende hidroxicloroquina y/o cloroquina.
JP2022044038A (ja) * 2020-09-04 2022-03-16 株式会社大石膏盛堂 ドネペジル含有経皮吸収液剤およびその製造方法
CN112656778A (zh) * 2020-12-28 2021-04-16 广东红珊瑚药业有限公司 一种压敏胶基质以及一种贴剂
US12270039B2 (en) * 2021-05-14 2025-04-08 Board Of Trustees Of Southern Illinois University Compositions and methods to increase oleic acid content in soybeans
US12270040B2 (en) * 2021-05-27 2025-04-08 Board Of Trustees Of Southern Illinois University Soybean lines with low saturated fatty acid and high oleic acid contents
JP2024526635A (ja) * 2021-07-08 2024-07-19 モンサント テクノロジー エルエルシー 新規の昆虫阻害タンパク質
WO2023136966A1 (en) * 2022-01-12 2023-07-20 Inari Agriculture Technology, Inc. Reduced height maize
WO2025103446A1 (zh) * 2023-11-16 2025-05-22 宜昌人福药业有限责任公司 含有多奈哌齐的透皮贴剂及其制备方法

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
NL134681C (enExample) 1966-04-26
US3546141A (en) 1966-08-08 1970-12-08 Mc Donnell Douglas Corp Phosphorus-nitrogen polymers and process
CA974518A (en) 1972-04-20 1975-09-16 Merz And Co. Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
EP0186087B1 (de) 1984-12-22 1989-08-23 Dr. Karl Thomae GmbH Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel
US4880633A (en) 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
DE3634016A1 (de) 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4837027A (en) 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
US4781924A (en) 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
ATE94384T1 (de) 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
DE3913734C2 (de) * 1989-04-26 1998-08-20 Roehm Gmbh Verwendung einer wäßrigen Hauthaftkleberlösung zur Herstellung einer mit Wasser leicht abwaschbaren Klebschicht
US5252588A (en) * 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
MY115126A (en) * 1990-04-27 2003-04-30 Seikisui Chemical Co Ltd Percutaneously absorbable eperisone or tolperisone preparation.
AU652952B2 (en) 1990-07-23 1994-09-15 Alza Corporation Oral osmotic device for delivering nicotine
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5123900A (en) * 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
JPH06199659A (ja) 1992-10-28 1994-07-19 Hisamitsu Pharmaceut Co Inc 経皮治療用装置
DE4310012A1 (de) * 1993-03-27 1994-09-29 Roehm Gmbh Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
US5424077A (en) 1993-07-13 1995-06-13 Church & Dwight Co., Inc. Co-micronized bicarbonate salt compositions
EP0757910B1 (en) * 1994-04-21 2002-09-11 Hisamitsu Pharmaceutical Co., Inc. Percutaneously administrable base composition and percutaneously administrable drug composition prepared therefrom
DE69517816T2 (de) 1994-09-14 2000-12-28 Minnesota Mining & Mfg Matrix für transdermale wirkstofffreisetzung
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
EP0799029A1 (en) 1994-12-21 1997-10-08 Theratech, Inc. Transdermal delivery system with adhesive overlay and peel seal disc
AU6032696A (en) 1995-06-07 1996-12-30 Cygnus Therapeutic Systems Pressure sensitive acrylate adhesive composition cross-linke d with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
DE19531342B4 (de) 1995-08-25 2007-11-29 Merz Pharma Gmbh & Co. Kgaa Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5958919A (en) 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
CA2264687C (en) 1996-10-24 2006-04-25 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
CN1174031A (zh) * 1997-04-23 1998-02-25 谢先运 双氯芬酸钠透皮控释贴膏
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
JP4205778B2 (ja) * 1998-04-17 2009-01-07 久光製薬株式会社 貼付製剤
DE19820999A1 (de) 1998-05-11 1999-11-18 Lohmann Therapie Syst Lts Laminat zum Aufbringen auf einen Akzeptor
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US20020192243A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
AU2002214364B2 (en) * 2000-11-06 2004-08-19 Samyang Biopharmaceuticals Corporation Transdermal drug delivery system with improved water absorbability and adhesion properties
EP1340496A4 (en) * 2000-11-07 2004-04-14 Hisamitsu Pharmaceutical Co PHARMACEUTICAL PREPARATION OF THE PERCUTANEOUS ABSORPTION TYPE
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US8728445B2 (en) 2001-05-01 2014-05-20 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences Hydrogel Compositions
US7250394B2 (en) 2001-08-20 2007-07-31 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
CA2459399C (en) 2001-09-04 2009-06-30 Trommsdorff Gmbh & Co. Kg Arzneimittel Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
JP4394443B2 (ja) * 2001-10-17 2010-01-06 久光製薬株式会社 経皮吸収型製剤
ITMI20012827A1 (it) * 2001-12-28 2003-06-28 Fidia Farmaceutici Formulazioni adesive transdermiche di diclofenac sodico
US7273619B2 (en) * 2002-01-17 2007-09-25 Samyang Corporation Transdermal composition of an antivomiting agent
UA83645C2 (ru) 2002-10-24 2008-08-11 Мерц Фарма Гмбх Унд Ко. Кгаа Фармацевтический продукт, который содержит производное 1-аминоциклогексана и ингибитор ацетилхолинестеразы, его применение
AU2004283431B2 (en) 2003-10-10 2009-09-10 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
WO2005037157A1 (en) * 2003-10-14 2005-04-28 Dermatrends, Inc. Enhancing transdermal administration of hydrophilic drugs
CN1870984A (zh) 2003-10-22 2006-11-29 莫茨药物股份两合公司 1－氨基环己烷衍生物用于调节淀粉样病变中原纤维生成Aβ肽的沉积的用途
US7740633B2 (en) 2003-10-23 2010-06-22 Trans1 Inc. Guide pin for guiding instrumentation along a soft tissue tract to a point on the spine
EP1684806B1 (en) 2003-11-21 2008-06-25 Memory Pharmaceuticals Corporation Compositions comprising l-type calcium channel blockers and cholinesterase inhibitors
US7176185B2 (en) 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
JP5179757B2 (ja) 2004-02-17 2013-04-10 トランセプト ファーマシューティカルズ， インコーポレイティド 口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法
US7670838B2 (en) 2004-05-24 2010-03-02 The Board Of Trustees Of The Leland Stanford Junior University Coupling of excitation and neurogenesis in neural stem/progenitor cells
WO2005115355A1 (ja) * 2004-05-28 2005-12-08 Hisamitsu Pharmaceutical Co., Inc. 貼付製剤
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20060078604A1 (en) 2004-10-08 2006-04-13 Noven Pharmaceuticals, Inc. Transdermal drug delivery device including an occlusive backing
DE602005010812D1 (de) 2004-11-22 2008-12-18 Hisamitsu Pharmaceutical Co Transdermales Pflaster enthaltend einen schmelzpunktsenkenden Hilfsstoff
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
WO2006076562A1 (en) 2005-01-11 2006-07-20 Teva Pharmaceutical Fine Chemicals S.R.L. Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
US20080138388A1 (en) * 2005-02-04 2008-06-12 Hisamitsu Pharmaceutical Co., Inc. Transdermal Absorption Patch
US20060188558A1 (en) * 2005-02-18 2006-08-24 Mylan Technologies, Inc. Transdermal systems having control delivery system
CA2604052C (en) 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
US7888422B2 (en) 2005-11-09 2011-02-15 Mylan Technologies Inc. Long-wearing removable pressure sensitive adhesive
WO2007110080A2 (en) * 2006-03-28 2007-10-04 Amcor Flexibles Denmark A/S A multilayer film free of halogens which is impermeable to aroma compounds
CN1895242B (zh) * 2006-04-13 2011-08-31 沈阳药科大学 双氯芬酸盐的透皮贴剂及制备方法
IL175338A0 (en) 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
CN101460156B (zh) 2006-05-08 2011-06-08 帝国制药株式会社 抗痴呆药的经皮吸收制剂
JP5097359B2 (ja) * 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
US9248104B2 (en) * 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
US20080107719A1 (en) 2006-11-08 2008-05-08 Sukhon Likitlersuang Transdermal drug delivery system
KR20090086565A (ko) 2006-12-01 2009-08-13 닛토덴코 가부시키가이샤 안정화된 도네페질 함유 접착 제제
BRPI0719308A2 (pt) 2006-12-01 2014-02-04 Nitto Denko Corp Método para supressão da coloração de preparação adesiva contendo donepzil e método para redução da quantidade de substâncias formadas relacionadas à donepezil.
CN101588802A (zh) * 2006-12-01 2009-11-25 日东电工株式会社 含有稳定化的多奈哌齐的贴剂
JP5403948B2 (ja) 2007-06-07 2014-01-29 久光製薬株式会社 メマンチン含有経皮吸収製剤
CN101801321B (zh) 2007-07-10 2014-07-02 敏捷治疗公司 原位密封的经皮输送装置
US9017301B2 (en) * 2007-09-04 2015-04-28 Mylan Technologies, Inc. Transdermal drug delivery systems comprising a coated release liner
JP2009203213A (ja) * 2008-02-28 2009-09-10 Kosumedei Seiyaku Kk 経皮吸収医薬組成物
DE102008013701A1 (de) 2008-03-11 2009-09-17 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit stabilisierter Membran
KR101454362B1 (ko) 2008-03-24 2014-10-23 아이큐어 주식회사 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제
EP2111857A1 (de) * 2008-04-25 2009-10-28 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon
US20090291127A1 (en) 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
PE20100371A1 (es) 2008-10-31 2010-06-01 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de malaria cerebral
US20100178037A1 (en) 2009-01-12 2010-07-15 Te-Wei Chen Display apparatus, video generation apparatus, and method thereof
US8784879B2 (en) 2009-01-14 2014-07-22 Corium International, Inc. Transdermal administration of tamsulosin
JP5758290B2 (ja) 2009-05-01 2015-08-05 久光製薬株式会社 経皮吸収型製剤
WO2011034323A2 (en) 2009-09-16 2011-03-24 Samyang Corporation Transdermal delivery system, method for manufacturing the same, and transdermal delivery method using the system
CN102573843B (zh) 2009-10-21 2014-09-24 帝国制药株式会社 含有多奈哌齐的经皮吸收型制剂
CN102048678A (zh) 2009-10-30 2011-05-11 北京隆旗生物科技有限公司 一种奥昔布宁的透皮吸收制剂及其制备方法与药物应用
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
JP2012236773A (ja) * 2009-12-16 2012-12-06 Goto Takeshi 抗認知症薬物の経皮吸収製剤
PT2519225E (pt) 2009-12-30 2015-07-27 Novartis Ag Tiras finas de nicotina extrudidas por fusão
US20100178307A1 (en) 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
WO2011105486A1 (ja) * 2010-02-24 2011-09-01 久光製薬株式会社 貼付剤
US20110244023A1 (en) * 2010-03-30 2011-10-06 Phosphagenics Limited Transdermal delivery patch
JP5665861B2 (ja) 2010-04-28 2015-02-04 久光製薬株式会社 ドネペジル含有経皮吸収製剤
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
NZ605352A (en) * 2010-06-30 2013-10-25 Nal Pharmaceuticals Ltd Process for producing glycosaminoglycans
US20140370076A1 (en) 2010-06-30 2014-12-18 Nal Pharmaceuticals, Ltd. Transdermal drug delivery system containing donepezil
EP2598119B1 (en) 2010-07-29 2018-09-19 Allergan, Inc. Preservative free brimonidine and timolol solutions
US8501816B2 (en) 2010-10-12 2013-08-06 Cerecor, Inc. Antitussive compositions comprising memantine
JP5699554B2 (ja) 2010-11-11 2015-04-15 富士通株式会社 ベクトル処理回路、命令発行制御方法、及びプロセッサシステム
US9844515B2 (en) 2010-11-17 2017-12-19 Hexal Ag Transdermal therapeutic system comprising buprenorphine
WO2012084969A1 (en) 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
CN103384533A (zh) * 2010-12-29 2013-11-06 法玛费尔姆有限责任公司 双氯芬酸二乙铵的改进透皮渗透的药用贴剂
TWI433904B (zh) 2011-01-12 2014-04-11 Taiwan Biotech Co Ltd 多奈哌齊經皮貼片
CN102775476B (zh) * 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
US8673338B2 (en) 2011-07-29 2014-03-18 Massachusetts Eye And Ear Infirmary Methods of delivering pharmaceutical agents
JP5808214B2 (ja) * 2011-09-30 2015-11-10 株式会社トクヤマ 貼付剤
KR101239150B1 (ko) 2012-02-28 2013-03-06 에스케이케미칼주식회사 도네페질-함유 경피흡수제제 및 그의 제조방법
US9408802B1 (en) * 2012-03-22 2016-08-09 Prosolus, Inc. Seven day drug in adhesive transdermal delivery
US9145907B2 (en) 2012-08-28 2015-09-29 Hsiutao Liang Pipe connector
US20140256690A1 (en) 2013-03-08 2014-09-11 Agile Therapeutics, Inc. Contraceptive method
WO2014174564A1 (ja) 2013-04-22 2014-10-30 祐徳薬品工業株式会社 メマンチン含有経皮吸収型貼付製剤
JP5415645B1 (ja) 2013-06-28 2014-02-12 久光製薬株式会社 貼付剤の製造方法、貼付剤及び包装体
US20160199317A1 (en) * 2013-08-30 2016-07-14 3M Innovative Properties Company Estradiol containing transdermal drug delivery systems and compositions
KR101827980B1 (ko) 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
WO2015053878A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
EP3069712B1 (en) * 2013-11-17 2020-09-23 MEDRx Co., Ltd. Transdermal colloidal solution agent
KR101485822B1 (ko) 2014-01-22 2015-01-23 주식회사 대웅제약 도네페질 또는 그의 염을 함유하는 경피흡수제제
JP2015151370A (ja) * 2014-02-14 2015-08-24 日東電工株式会社 貼付製剤
CA2951706A1 (en) 2014-06-24 2015-12-30 KAT Transdermals LLC Transdermal delivery system
EP3169317B1 (en) * 2014-07-18 2020-04-08 Buzzz Pharmaceuticals Limited Oxymorphone transdermal patch
JP6577795B2 (ja) 2014-09-03 2019-09-18 日東電工株式会社 ビスホスホネート剤を含む細胞性免疫用ワクチン医薬組成物
WO2016046675A1 (en) 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of neurological diseases
MY181540A (en) 2014-12-18 2020-12-28 Icure Pharm Inc Transdermal composition containing donepezil as active ingredient
EP3250219A4 (en) 2015-01-28 2018-10-03 DNX Biotech, LLC Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life
US20180185298A1 (en) 2015-06-22 2018-07-05 Corium International, Inc. Transdermal Adhesive Composition Comprising A Poorly Soluble Therapeutic Agent
US20180207108A1 (en) 2015-07-27 2018-07-26 Hisamitsu Pharmaceutical Co., Inc. Method for Manufacturing Asenapine-Containing Patch
RU2737464C2 (ru) 2015-12-30 2020-11-30 Кориум Интернэшнл, Инк. Системы и способы длительного трансдермального введения
CN105693556A (zh) 2016-03-01 2016-06-22 巴斯特医药科技（常州）有限公司 卡巴拉汀酒石酸盐的转化方法及其产物制成的贴片
WO2017223402A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
KR102508993B1 (ko) 2016-07-27 2023-03-10 코리움, 인크. 메만틴 경피 송달 시스템
US20180028463A1 (en) 2016-07-27 2018-02-01 Corium International Inc. Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug
AU2017302305A1 (en) 2016-07-27 2019-02-14 Corium, LLC. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
WO2019023499A1 (en) 2017-07-26 2019-01-31 Corium International, Inc. TRANSDERMAL DELIVERY SYSTEM WITH MICROPOROUS MEMBRANE HAVING SOLVENT FILLED PORES

Also Published As

Publication number Publication date
CN109789106B (zh) 2023-06-27
CN109789133A (zh) 2019-05-21
KR20190035801A (ko) 2019-04-03
KR102406536B1 (ko) 2022-06-08
SG11201900692WA (en) 2019-02-27
MX2022006681A (es) 2022-07-11
US20210015761A1 (en) 2021-01-21
WO2018022817A1 (en) 2018-02-01
US10300025B2 (en) 2019-05-28
AU2017301928A1 (en) 2019-02-14
CA3032044A1 (en) 2018-02-01
US20220016045A1 (en) 2022-01-20
CN116270551A (zh) 2023-06-23
AU2017302307A1 (en) 2019-02-14
JP2019525932A (ja) 2019-09-12
US9993466B2 (en) 2018-06-12
KR20230098349A (ko) 2023-07-03
US20190247321A1 (en) 2019-08-15
AU2023203618B2 (en) 2025-09-18
MX2019001103A (es) 2019-09-27
KR20190034601A (ko) 2019-04-02
US20250375396A1 (en) 2025-12-11
KR20230097203A (ko) 2023-06-30
WO2018022815A2 (en) 2018-02-01
US11103463B2 (en) 2021-08-31
AU2023203618A1 (en) 2023-07-06
JP2022140751A (ja) 2022-09-27
EP3490541B1 (en) 2025-07-09
CA3031945C (en) 2025-09-23
US10307379B2 (en) 2019-06-04
AU2017301928B2 (en) 2023-04-06
KR102406528B1 (ko) 2022-06-08
US20190247320A1 (en) 2019-08-15
RU2019105279A (ru) 2020-08-27
EP3490558A1 (en) 2019-06-05
WO2018022816A1 (en) 2018-02-01
EP3490540A1 (en) 2019-06-05
KR102555208B1 (ko) 2023-07-17
KR20220082929A (ko) 2022-06-17
AU2025205205A1 (en) 2025-07-24
AU2017302306A1 (en) 2019-02-14
JP7251033B2 (ja) 2023-04-04
US20180028512A1 (en) 2018-02-01
US20180028463A1 (en) 2018-02-01
KR20220082928A (ko) 2022-06-17
JP7153010B2 (ja) 2022-10-13
WO2018022815A3 (en) 2018-03-08
AU2023204240A1 (en) 2023-07-27
AU2023203616A1 (en) 2023-07-06
US20240156747A1 (en) 2024-05-16
JP2022121629A (ja) 2022-08-19
JP7071330B2 (ja) 2022-05-18
KR102406482B1 (ko) 2022-06-08
KR102545649B1 (ko) 2023-06-22
KR20190032512A (ko) 2019-03-27
JP2019523268A (ja) 2019-08-22
CN116966166A (zh) 2023-10-31
JP2022093707A (ja) 2022-06-23
EP3490541A2 (en) 2019-06-05
US20250325496A1 (en) 2025-10-23
CA3032044C (en) 2024-10-01
CA3031945A1 (en) 2018-02-01
KR102545643B1 (ko) 2023-06-21
CN109789106A (zh) 2019-05-21
CN109789105B (zh) 2022-12-27
CN109789105A (zh) 2019-05-21
KR20220082098A (ko) 2022-06-16
US20250375395A1 (en) 2025-12-11
JP2019523270A (ja) 2019-08-22
US20180028462A1 (en) 2018-02-01
US20180028663A1 (en) 2018-02-01
US20180235901A1 (en) 2018-08-23
KR20230109782A (ko) 2023-07-20
RU2019105279A3 (enExample) 2020-12-23
CA3032148A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
MX394249B (es) Sistema de suministro transdermico de donepezilo.
MX2024010140A (es) Nuevos metodos.
AR095160A1 (es) Formulaciones farmacéuticas a prueba de alteraciones
JP2015057451A5 (enExample)
BR112016000194A8 (pt) forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
MX387061B (es) Formulación farmacéutica en aerosol formadora de película polimérica que comprende un agente activo y povidona como agente inhibidor de la precipitación de cristales de fármaco/polímero formador de película hidrofílico.
GB2529789A (en) Transdermal Delivery system
MX2021001905A (es) Preparacion farmaceutica que tiene excelentes propiedades de disolucion, que contiene esomeprazol y bicarbonato de sodio.
JP2015523407A5 (enExample)
JP2017506624A5 (enExample)
AR096402A1 (es) Medicamento de metformina y dihidroquercetina
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
CR20140358A (es) Sistema para la administración de fármacos
EA201690974A1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
MX2020007293A (es) Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
WO2014111790A3 (en) Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
JOP20190054B1 (ar) مركبات إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
AR096223A1 (es) Pastilla de nicotina para administración oral
TW201642854A (en) Fixed dose combination for pain relief without edema
WO2020022976A3 (en) A formulation comprising dexketoprofen
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
AR104177A1 (es) Sistema para la administración de fármacos en la glándula lagrimal
JP2017057199A5 (enExample)